The Medicare GLP‑1 Bridge program went into effect July 1, 2026. If you qualify, you could access a weight loss medication for as little as a $50 copay. Doctor-guided treatment for $39 for your first month of membership + cost of medication.*
$39 promotional rate available for new subscribers only. After the first month, monthly membership fee increases to $79/month. Promotional pricing not available in all states. Medications and diagnostic services not included in membership subscription. See full terms here
An estimated
3.8 million Medicare beneficiaries could qualify for the Bridge.*
Obesity affects roughly 1 in 4 people on Medicare.*
Here's what's changing for coverage.
Starting July 1, 2026, a new Medicare program called the GLP-1 Bridge began offering temporary coverage for FDA-approved weight loss medications. It's open to people enrolled in Medicare Part D who meet the eligibility requirements, and the program only runs for a limited amount of time.
If you were told in the past that Medicare doesn't cover your weight loss medication, it's worth checking your eligibility again.
How Mochi helps
All medication doses below available for as little as a $50 co-pay.
1In a 72-week trial (ATTAIN-1) of the 36 mg dose in non-diabetic adults with obesity or overweight plus a weight-related condition, with diet and exercise, vs. ~2% for diet and exercise alone. Wharton S, et al. N Engl J Med. 2025;393(18):1796-1806. doi:10.1056/NEJMoa2511774
Foundayo®
Once-daily oral pill, all doses.
2In a 68-week trial (STEP UP) of Wegovy HD injection 7.2 mg in non-diabetic adults with obesity, with diet and exercise, vs. ~4% for diet and exercise alone. Wharton S, et al; STEP UP trial group. Lancet Diabetes Endocrinol. 2025;13(11):949-963. doi:10.1016/S2213-8587(25)00226-8
Wegovy® pen
Weekly injection, all doses.
3In a 64-week trial (OASIS 4) of Wegovy tablets 25 mg in non-diabetic adults with obesity or overweight plus a weight-related condition, with diet and exercise, vs. ~2% for diet and exercise alone. Wharton S, et al. N Engl J Med. 2025;393(11):1077-1087. doi:10.1056/NEJMoa2500969
Wegovy® tablet
Once-daily oral pill, all doses.
4In a 72-week trial (SURMOUNT-1) of the 15 mg dose in non-diabetic adults with obesity or overweight plus a weight-related condition, with diet and exercise, vs. ~3% for diet and exercise alone. Jastreboff AM, et al. N Engl J Med. 2022;387(3):205-216. doi:10.1056/NEJMoa2206038
Zepbound®
Weekly injection (Kwikpen only, all doses).
Prescription medications require a written prescription from a licensed provider. Speak with a provider to determine if a prescription medication is appropriate for you. Medications and diagnostic services not included in membership subscription.
FAQ
Everything you need to know
FAQ
01
What is the Medicare GLP‑1 Bridge?
02
How long is the Bridge available?
03
What if I'm not eligible?
Expertise
Choose a board certified obesity medicine provider and a registered dietitian who are ready to work with you to build a plan that fits your history and goals.
400+ board certified
Pricing
Mochi membership brings together provider access, coaching, support, and treatment options in one guided experience.
For iOS & Android
